Tech Company Financing Transactions
Vaxinano Funding Round
On 10/30/2024, Vaxinano raised $6.5 million in funding from Nord France Amorcage, Wiseed and Bpifrance.
Transaction Overview
Company Name
Announced On
10/30/2024
Transaction Type
Venture Equity
Amount
$6,500,000
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to accelerate its flagship vaccines and immuno-therapies targeting leishmaniasis, toxoplasmosis, and colibacillosis into clinical trials.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
84 rue du docteur Yersin
Lille, 59000
France
Lille, 59000
France
Phone
Undisclosed
Website
Email Address
Not Recorded
Overview
Drawing on over 30 years of industrial and academic expertise in vaccines and nanoparticles (NPs) by Professor Didier Betbeder, Vaxinano has developed a unique mucosal immunotherapy and vaccine platforms to protect against infection and transmission. Through numerous collaborations and publications in Europe and South America, the platform has been applied to a wide variety of animals, including primates and pets, demonstrating excellent safety and efficacy profiles.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jonathan Stauber
Browse more venture capital transactions:
Prev: 10/30/2024: Sapien venture capital transaction
Next: 10/30/2024: Diffblue venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs